Pomerantz Law Firm Investigates Potential Securities Fraud Claims Against Semler Scientific Inc.

Pomerantz Law Firm Probes Semler Scientific Inc.

Pomerantz LLP has initiated an investigation concerning potential claims from investors of Semler Scientific Inc. (NASDAQ: SMLR), following significant disclosures made in the company's recent annual report. The law firm is reaching out to investors, encouraging them to come forward if they have experienced any losses linked to the company's actions.

The investigation revolves around the possible involvement of Semler and certain members of its executive team in securities fraud or other unlawful business practices. Recent developments have raised red flags among investors, as the company has faced scrutiny from the U.S. Department of Justice (DOJ). On February 28, 2025, Semler released its annual report for 2024, where it disclosed a risk that the DOJ might file a civil complaint related to the company's conduct.

Key Details from the Annual Report

The annual report mentioned the reception of an initial civil investigative demand from the DOJ in July 2017, focusing on reimbursement claims concerning their peripheral artery disease device, QuantaFlo. Notably, the report stated that negotiations to settle with the DOJ in February 2025 had not yielded a favorable outcome. The alarming news triggered a significant stock price decline, with shares plummeting by $4.03, equivalent to a 9.4% drop, closing at $38.89 per share on March 3, 2025.

Background on Pomerantz LLP

Founded over 85 years ago by Abraham L. Pomerantz, the firm has established itself as a leader in corporate and securities class litigation. Pomerantz's commitment to advocating for victims of securities fraud and corporate misconduct has led to numerous multimillion-dollar recoveries on behalf of affected investors. Their extensive experience and dedication to justice make them a formidable ally for investors seeking recompense for losses.

Encouraging Investors to Act

Investors of Semler Scientific Inc. affected by these recent disclosures are encouraged to reach out to Pomerantz LLP for potential inclusion in this investigation. Danielle Peyton, an attorney at Pomerantz, is available at [email protected] or 646-581-9980, ext. 7980 for inquiries. The law firm's proactive approach signifies their aim to protect and uphold the rights of investors facing potential losses due to corporate malfeasance.

With the investigation ongoing, it remains critical for stakeholders to stay informed about any developments regarding Semler Scientific. As more information surfaces, investors should consider the implications on their portfolios and be prepared to take necessary actions as guided by their advisors.

In a climate where corporate transparency is paramount, the scrutiny of companies like Semler Scientific underscores the necessity for vigilance among investors. As Pomerantz LLP works to navigate the complexities of these allegations, it also highlights the broader concerns surrounding integrity in the business realm.

For more updates, stay tuned to Pomerantz's official communications as they pursue justice for their clients, reinforcing their relentless commitment to combating securities fraud and advocating for responsible corporate governance.